QuidelOrtho Corp. Stock
QuidelOrtho Corp. Stock
Pros and Cons of QuidelOrtho Corp. in the next few years
Pros
Cons
Performance of QuidelOrtho Corp. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
QuidelOrtho Corp. | 0.540% | - | -5.584% | -54.423% | -45.149% | -58.648% | - |
Boston Scientific | 0.740% | -0.730% | 7.937% | 42.647% | 32.193% | 88.001% | 105.687% |
Waters Corp. | 2.070% | 2.648% | -5.418% | 10.556% | -1.159% | 18.452% | 53.077% |
Illumina Inc. | -5.450% | -4.165% | -7.092% | -38.410% | -14.770% | -65.786% | -62.274% |
Comments
News
QuidelOrtho Appoints Brian J. Blaser as President and Chief Executive Officer
QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point of care settings, clinical labs and
QuidelOrtho To Report First Quarter 2024 Financial Results
QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and
QuidelOrtho Adds Fentanyl Test to Its Vitros® Systems as a MicroTip® Partnership Assay
QuidelOrtho Corporation (Nasdaq: QDEL) has added the ARK™ Fentanyl II Assay to its U.S. Vitros® XT 7600 and 5600 Integrated Systems as well as its Vitros® 4600 Chemistry System menu of assays as a